Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
Total Valuation
IN8bio has a market cap or net worth of $11.95M. The enterprise value is $12.55M.
Market Cap$11.95M
Enterprise Value$12.55M
Share Statistics
IN8bio has 81.26M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81.26M
Owened by Insiders29.90%
Owened by Instutions26.93%
Financial Efficiency
IN8bio’s return on equity (ROE) is -2.10 and return on invested capital (ROIC) is -156.02%.
Return on Equity (ROE)-210.23%
Return on Assets (ROA)-145.33%
Return on Invested Capital (ROIC)-156.02%
Return on Capital Employed (ROCE)-170.41%
Revenue Per Employee$208,222.222
Profits Per Employee-$1,770,833.333
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of IN8bio is -0.45. IN8bio’s PEG ratio is 0.01.
PE Ratio-0.45
PS Ratio0.00
PB Ratio0.95
Price to Fair Value0.95
Price to FCF-0.57
Price to Operating Cash Flow-0.57
PEG Ratio0.01
Income Statement
In the last 12 months, IN8bio had revenue of $3.75M and earned -$31.88M in profits. Earnings per share was -$0.75.
Revenue$3.75M
Gross Profit$1.86M
Operating Income-$31.88M
Pretax Income-$31.88M
Net Income-$31.88M
EBITDA-28.66M
Earnings Per Share (EPS)-0.75
Cash Flow
In the last 12 months, operating cash flow was -$24.97M and capital expenditures -$143.00K, giving a free cash flow of -$25.11M billion.
Operating Cash Flow-$24.97M
Free Cash Flow-$25.11M
Free Cash Flow per Share-$0.31
Dividends & Yields
IN8bio pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-176.10%
Earnings Yield-221.00%
Stock Price Statistics
Beta1.64
52-Week Price Change-86.49%
50-Day Moving Average0.24
200-Day Moving Average0.39
Relative Strength Index (RSI)26.46
Average Volume (3m)1.21M
Important Dates
IN8bio upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
IN8bio as a current ratio of 4.08, with Debt / Equity ratio of 0.35
Current Ratio4.08
Quick Ratio4.08
Debt to Market Cap0.37
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, IN8bio has paid -$8.23M in taxes.
Income Tax-$8.23M
Effective Tax Rate0.00%
Enterprise Valuation
IN8bio EV to EBITDA ratio is -0.25, with an EV/FCF ratio of -0.32.
EV to Sales0.00
EV to EBITDA-0.25
EV to Free Cash Flow-0.32
EV to Operating Cash Flow-0.32
Balance Sheet
IN8bio has $4.00M in cash and marketable securities with $5.47M in debt, giving a net cash position of $1.47M billion.
Cash & Marketable Securities$4.00M
Total Debt$5.47M
Net Cash$1.47M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.27
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for IN8bio is $3.07, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$3.07
Price Target Upside1946.67%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast38.53%